No PEARLs of survival with palbociclib plus endocrine therapy compared with capecitabine, but QoL better Presented ByProf. Miguel Martín Jiménez, Complutense University of Madrid, Spain TrialPhase 3, PEARL ConferenceESMO 2021 19 November, 2021 09:45
